Diabetes presentation dr mohammed abuelkhair logo

  • 209 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
209
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
3
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Opportunities to enhance prescribingefficiency for patients with diabetes in Abu Dhabi without compromising care Dr Mohammed Abuelkhair Head, Pharma/Medicine & Medical Product Regulation
  • 2. G A S N O JC IE O L A D BE TV S  T eg a o teP am c v iln ea dR t n l e ic eU e h o l fh h r a o ig a c n aio a M d in s po rmo a H A is oid nif a dpo oeo t a du rga f t A D t e ty n rm t pim l rg pecib ga du e rsr in n s.  Srtg stosa dsric s r po id dt e c ua ete t e ie, o l n ev e ae rv e o n o rg h a , u eo e id n eb sdc ic l n c s efciv n s s f v e c - ae l a a d o t f t e es in - e inom t nind c io m k ga o gh at c r po id r, fr aio e is n a in m n e l ae rv es h c n u es n p lym k r. o s m r a d oic a es  T ea o tea d w s oa ayec r n t am n h im fh u it a t n l z ur tr t e t e e a po c e a o gp t ns it T p 2d b tsT D )a d p ra h s m n aie t w h y e ia ee ( 2 M n c m aew hinen t n ltn ad . S c n l ass te o p r it traio a s d rs e o dy ses h a , e tn o d frn m n g m n a po c e/rsr in xe t f if e t a a e e t p ra h s ecib g e p p t r a o gd frn fcit s at n m n if e ta ilie. e e
  • 3. MT O S EH D A d o 5 1rn o p t ns co s fcit s rain u it f 6 a d m aie t a rs 3 a ilie t t g e T D p t ns v r y a. 2 M aie t o e 1 e r 1s e iais d b ts e tr p c lt ia ee c ne, 1g v rm n ( K C d b ts e tr o en e tS M ) ia ee c ne 1in e e d n piv t sco h s it d p n e t r ae e tr o p a D t in ld de tn o p t n m n oin ( P l id , aa c e xe t f aie t o itr g B , ip s u H A c w ig trn lu cio , ec , oa g c m du s b 1 , e h, e a fn t n t.) rl l e ic rg y pecib d w eh rh s pecib da m x a d ss rsr e , h te tee rsr e t a im l o e ( IEg id n e b fr in uin , w eh r s l t am n N C u a c ) eoe s l s h te in uin r t e t e d ly da din uintp . ea e n s l y e 
  • 4. M JRFN IG AO IDN SPecib g rsr in H hu eo p tn poe tddu s c d g ig s f ae t rtce rg in l in : u  E p n iv m d ie rlaem d in se . m t r in x e s e o if d ee s e ic e ( .g ef m o M / llz eM )v ru g n r s n adrlae R gic id R es s e eic t d r ee s a a pe aaio s rp rt n  Gipin in ld gsa l t 5 m T IED I d s l t s c in itgipin 0 g WC AL oe u Y  E p n iv in uin s c a in uingag e x e s e s l s u h s s l lrin H hu eo gim p id ig s f l e ir eQ ait o c r u ly f ae H A ce od din8 % t1 0 )o al aie t w h b 1 rc re ( 3 o 0 % f lp t ns it d b ts ia ee L s ta 5 % o p t ns a arc re H A c f es h n 0 f aie t h d e od d b 1 o <
  • 5. M JRFN IG AO IDN SNo of patients at each participatingfacility Types of medical intervention used to control diabetes
  • 6. M JRFN IG AO IDN SHbA1c Types of medical intervention used to control diabetes
  • 7. M JRFN IG AO IDN SPrescribing of agents to control Trends in prescribing of oral anti-hyperglycemia hyperglycemics.   Independent  Government  Specialist    hospital  Hospital Center (Private)         Metformin  39 % 85.5 %  87.6 %               Sulphonylurea 47 % 57.4 %  50.5 %           Glitazone 13 % 20.3 % 12.4 %             Prandial regulators 0 % 3.1 % 5.7 %         Gliptins 33% 64.5 % 61 %   Newer Agents      (eg:        Exanetide) 0 % 7.4 % 3.8 %           Older anti  2% 0.8 % 1.0 % -hyperglycemic agents  (eg:Acarbose)
  • 8. M JRFN IG AO IDN STrends in prescribing of generics Trends in prescribing sitagliptin
  • 9. M JRFN IG AO IDN STrends in prescribing Insulins
  • 10. M JRFN IG AO IDN STrends in prescribing sulphonylureas Gliclazide modified release preparations may be useful in patients who suffer with hypoglycaemia with standard release preparations. However the cost of the modified release tablets is significantly higher than standard tablets. In addition Glimepiride is significantly more expensive than Gliclazide There is no strong evidence to suggest increased efficacy or lower incidence of side effects from Glimepiride use.
  • 11. M JRFN IG A D C N L S N AO IDN S N O C U I SO W et aec s c udb rd c db e sim t o t o l e e u e y s a po im tl 3 % tru hfl w ginen t n l p rx aey 0 ho g ol in traio a o g id l e a drd c guilaio o e p n iv u ein s n e u in tist n f x e s e m d ie rlaepe aaio s o if d ee s rp rt n C r c udas im rv db rg lr o itr go ae o l l o po e y e ua m n oin f H A c e es b 1 lv l It d cio o P am c B n f M n g m n nr u t n f h r a y e eit a a e e t o Ss m s o l as h l im rv a po r t s p yt s h ud l ep po e p rpiae t e o e w ec r a drd c c s . I a d io , in rae is ae n e u e o t n d it n ce s s IN pecib g h l m n o c m l n e a w l N rsr in , ep o itr o pia c , s el a m n o d ss f rg pecib d e . s t s s o itr o e o du s rsr e , .g t ina